Yazar "Erdogmus, Nagehan" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • [ X ]
    Öğe
    Bladder Cancer Metastases to the Temporal Bone
    (Lippincott Williams & Wilkins, 2011) Yildirim-Baylan, Muzeyyen; Erdogmus, Nagehan; Cureoglu, Sebahattin; Paparella, Michael M.
    Bladder cancer is the second most commonly occurring cancer of the genitourinary tract. Transitional carcinoma of the bladder, the most prevalent type, is very aggressive and can metastasize early (1). The most frequent sites of bladder cancer metastases are the lymph nodes, liver, lung, bone, and adrenal gland. Bladder cancer is rarely reported to metastasize to the temporal bone (1% of cases) (2). The most common primary tumors that metastasize to the temporal bone are breast (10%), lung (6%), and prostate (5%). In this study, a case of metastatic tumor of the temporal bone from transitional cell carcinoma of the bladder will be presented.
  • [ X ]
    Öğe
    Effects of chlorhexidine/benzydamine mouth spray on pain and quality of life in acute viral pharyngitis: A prospective, randomized, double-blind, placebo-controlled, multicenter study
    (Sage Publications Inc, 2010) Cingi, Cemal; Songu, Murat; Ural, Ahmet; Yildirim, Muzeyyen; Erdogmus, Nagehan; Bal, Cengiz
    We conducted a prospective, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy of chlorhexidine gluconate/benzydamine HCl mouth spray for reducing pain and improving quality of life in patients with acute viral pharyngitis. Prior to treatment, patients rated the intensity of their pain on a visual analog scale and evaluated their quality of life on the 36-Item Short-Form Health Survey. Patients were then randomized to receive either paracetamol (acetaminophen) plus chlorhexidine/benzydamine or paracetamol plus placebo for 7 days. On days 3 and 7 of treatment, the participants again rated the intensity of their pain, and on day 7, they again rated their quality of life. A total of 164 patients were evaluable at study's end-80 in the chlorhexidine/benzydamine group and 84 in the control group. A comparison of self-evaluations revealed that the active treatment group reported less pain on both day 3 (p < 0.001) and day 7 (p = 0.002). Likewise, the chlorhexidine/benzydamine group reported a significantly better quality of life on day 7 (p < 0.001). Chlorhexidine/benzydamine was well tolerated, and no serious adverse events were observed.